Business

Watson Pharma.

Reports last week suggested that drug maker Watson Pharmaceuticals Inc. is in talks to buy European counterpart Actavis. Citing unidentified sources, Reuters said the Parsippany, N.J., company could pay up to $7.3 billion for privately held Actavis. Both companies declined to comment. In May, Watson bought generics maker Specifar Pharmaceuticals of Greece in a deal valued at $563.1 million.

Advertisement